Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

A bidirectional relationship exists between metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), and sarcopenia, with each worsening the prevalence and prognosis of the other. Hepatokines have recently been shown to affect skeletal...

🗓️ 2026-06-11
📰 Publication: Molecular Metabolism
Read MoreHepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

Endocannabinoid system and skeletal muscle health: insights from cannabidiol.

The endocannabinoid (EC) system is a complex network comprising endogenous ligands, enzymes responsible for their synthesis and degradation, and various receptors (including CB1 and CB2). Present in many peripheral tissues, including skeletal muscle, EC system is now recognized to influence...

🗓️ 2026-06-10
📰 Publication: Molecular Metabolism
Read MoreEndocannabinoid system and skeletal muscle health: insights from cannabidiol.

Sarcopenic obesity and dementia risk: Primary associations and landmark analyses of muscle strength and body composition trajectories.

BACKGROUND AND AIMS

Sarcopenic obesity (SO) has been proposed as a risk factor for cognitive impairment. Yet evidence is inconsistent and often limited by heterogeneous definitions and lack of longitudinal assessments. This study aimed to examine associations of SO with all-cause...

🗓️ 2026-06-07
📰 Publication: Clinical Nutrition
Read MoreSarcopenic obesity and dementia risk: Primary associations and landmark analyses of muscle strength and body composition trajectories.

Muscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

BACKGROUND

Muscle-adipose aging reflects interactions between body composition changes and chronic inflammatory processes, but age-related patterns in these measures across ethnically diverse populations remain incompletely described. Understanding population-specific patterns is crucial for developing tailored prevention and intervention strategies. We aimed to...

🗓️ 2026-06-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

Positive allosteric modulator selective for adult muscle nicotinic acetylcholine receptor.

The muscle nicotinic acetylcholine receptor (AChR) is the key mediator of neuromuscular signal transmission and is essential for all voluntary movement in our body. In this study, we present DC-98-LC74, a positive allosteric modulator (PAM) for the adult skeletal muscle-type...

🗓️ 2026-06-02
📰 Publication: Proceedings Of The National Academy Of Sciences Of The United States Of America
Read MorePositive allosteric modulator selective for adult muscle nicotinic acetylcholine receptor.

Longitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.

BACKGROUND

Late-onset Pompe disease (LOPD) is a progressive metabolic myopathy characterised by lysosomal glycogen accumulation and leading to secondary disruptions in autophagy and cellular energy metabolism. While enzyme replacement therapy (ERT) has improved outcomes, early detection remains critical, because irreversible muscle...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLongitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.

Sema4A Protects Against Muscle Atrophy and Promotes Repair by Regulating Intracellular Metabolic Signalling.

BACKGROUND

Skeletal muscle atrophy is a debilitating condition associated with diverse diseases and clinical interventions. Although triggers such as glucocorticoid excess or direct muscle injury disrupt the balance between protein homeostasis and tissue repair, the upstream molecular signals that actively preserve...

🗓️ 2026-05-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSema4A Protects Against Muscle Atrophy and Promotes Repair by Regulating Intracellular Metabolic Signalling.

Food-derived bioactive peptides in gut-muscle Axis regulation: Potential and challenges from microbiota homeostasis to muscle metabolism remodeling.

The global population is aging at an accelerating pace, and sarcopenia has emerged as a central challenge to elderly health. Food-derived bioactive peptides, as natural functional compounds, can interact significantly with the gut microbiota, thereby indirectly influencing muscle metabolism and...

🗓️ 2026-05-22
📰 Publication: Food Research International
Read MoreFood-derived bioactive peptides in gut-muscle Axis regulation: Potential and challenges from microbiota homeostasis to muscle metabolism remodeling.

Automated abdominal aortic calcification, muscle health and incident falls: the UK Biobank Imaging Study.

Emerging evidence suggests that vascular disease is linked with poorer muscle strength and higher falls risk. We evaluated the association between abdominal aortic calcification (AAC), scored using a well-established and validated 24-point machine learning algorithm (ML-AAC24), with magnetic resonance imaging-derived...

🗓️ 2026-05-21
📰 Publication: Journal Of Bone And Mineral Research
Read MoreAutomated abdominal aortic calcification, muscle health and incident falls: the UK Biobank Imaging Study.

Heme Metabolism-Derived Carbon Monoxide Regulates Skeletal Muscle Function.

BACKGROUND

Heme oxygenases, HO-1 (Hmox1) and HO-2 (Hmox2), regulate skeletal muscle homeostasis by degrading heme and generating carbon monoxide (CO), a bioactive signalling molecule. Although HO-1 is known to influence muscle fibre composition and mitochondrial function, the role of HO-2 in...

🗓️ 2026-05-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHeme Metabolism-Derived Carbon Monoxide Regulates Skeletal Muscle Function.

Control of muscle mass during growth and aging: Clinical targets and pathways.

Muscle mass is a strong indicator of overall health in older adults. In healthy individuals, an adequate muscle mass is maintained through a balance between anabolic pathways, such as the mTOR pathway (mammalian target of rapamycin), and catabolic pathways, including...

🗓️ 2026-05-14
📰 Publication: Best Practice & Research Clinical Endocrinology & Metabolism
Read MoreControl of muscle mass during growth and aging: Clinical targets and pathways.

Muscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study.

BACKGROUND

Sarcopenia is inconsistently defined, and its definition might not adequately capture muscle failure, underlying disability, and other adverse outcomes in older adults. We aimed to develop and validate an evidence-based, outcome-driven model of muscle failure.

METHODS

In this derivation and multicohort validation...

🗓️ 2026-05-13
Read MoreMuscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study.

MyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

BACKGROUND

Muscle atrophy occurs during physiological (i.e., fasting) and pathological conditions (i.e., cancer) and anticipates death. Since not all patients will undergo muscle wasting, it would be highly useful to identify them soon to intervene early. We aim to generate a...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

RAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

BACKGROUND

Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end-products (RAGE) is expressed by several cell types and sustains the inflammatory response in...

🗓️ 2026-05-09
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 – Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 – The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89–94.

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014; 5: 1–3.

Argiles JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology 2015; 22: 100–106.

Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015; 6: 197–207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!